Non-myeloablative stem cell transplant (NMSCT) in AML, ALL, and MDS: Disappointing outcome for patients with advanced phase disease.

被引：0
|
作者：
Rezvani, K
Lalancette, M
Szydlo, R
Mackinnon, S
Blaise, D
Slavin, S
Alessandrino, EP
Michallet, M
Niederwieser, N
Apperley, J
Frassoni, F
机构：
[1] Hammersmith Hosp, London, England
[2] UCL, London, England
[3] Inst J Paoli I Calmettes, F-13009 Marseille, France
[4] Hadassah Univ, Jerusalem, Israel
[5] Policlin San Matteo, I-27100 Pavia, Italy
[6] Hop Edouard Herriot, Lyon, France
[7] Univ Leipzig, D-7010 Leipzig, Germany
[8] Osped San Martino Genova, Genoa, Italy
来源：
BLOOD | 2000年 / 96卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
2061
引用
收藏
页码：479A / 479A
页数：1
相关论文
共 50 条
  • [11] The importance of patient selection in non-myeloablative stem cell transplant (NMSCT) for acute and chronic leukemia, myelodysplastic syndrome, and myeloma.
    Lalancette, M
    Michallet, M
    Szydlo, R
    Rezvani, K
    Mackinnon, S
    Blaise, D
    Finke, J
    Slavin, S
    Alessandrino, EP
    Niederwieser, D
    Frassoni, F
    Gahrton, G
    Apperley, J
    BLOOD, 2000, 96 (11) : 199A - 199A
  • [12] Favorable outcome of non-myeloablative stem cell transplant (NMSCT) for chronic myeloid leukaemia (CML) in first chronic phase: A retrospective study of the European Group for Blood and Marrow Transplantation (EBMT).
    Lalancette, M
    Rezvani, K
    Szydlo, R
    Mayer, J
    Blaise, D
    Zander, A
    Michallet, M
    Slavin, S
    Frassoni, F
    Gahrton, G
    Niederwieser, D
    Apperley, J
    BLOOD, 2000, 96 (11) : 545A - 545A
  • [13] Favorable outcome of non-myeloablative stem cell transplant (NMSCT) for chronic myeloid leukaemias (CML) in first chronic phase: a retrospective study of the European Group for Blood and Marrow Transplantation (EBMT)
    Lalancette, M
    Rezvani, K
    Szydlo, R
    Mayer, J
    Blaise, D
    Zander, A
    Michallet, M
    Slavin, S
    Frassoni, F
    Niederwieser, D
    Apperley, J
    BONE MARROW TRANSPLANTATION, 2001, 27 : S279 - S279
  • [14] Non-myeloablative allogeneic stem cell transplant: Achievements and perspectives
    Saito, T
    Mineishi, S
    EXPERIMENTAL ONCOLOGY, 2001, 23 (01): : 4 - 10
  • [15] Non-myeloablative allografting for patients with myelodysplastic syndrome (MDS) and acute myeloid leukaemia (AML).
    Taussig, DC
    Cavenagh, JD
    Davies, AJ
    Oakervee, H
    Syndercombe-Court, D
    Kelsey, SM
    Barnett, MJ
    Rohatiner, A
    Lister, A
    BLOOD, 2002, 100 (11) : 409A - 410A
  • [16] Non-myeloablative stem cell transplant: A dose-finding study
    Bron, D
    Zachee, P
    Maertens, J
    Doyen, C
    Van den Berghe, P
    Ferrant, A
    Noens, L
    Schroyens, W
    Selleslag, D
    Demuynck, H
    Triffet, A
    De Meuter, A
    Boogaerts, M
    BLOOD, 2002, 100 (11) : 398B - 398B
  • [17] Allogeneic stem cell transplantation using non-myeloablative transplant regimens
    Körbling, M
    Khouri, I
    HIGH-DOSE THERAPY AND TRANSPLANTATION OF HAEMATOPOIETIC STEM CELLS, 2000, : 175 - 184
  • [18] Non-myeloablative stem cell transplantion in patients with AML and poor risk MDS: Experience from a single centre, Manchester Royal Infirmary, UK
    Tholouli, E
    Ibbottson, Y
    Pottinger, B
    Osborne, D
    Garg, M
    Goldstone, J
    McGaw, D
    Burthem, J
    Lucas, G
    BONE MARROW TRANSPLANTATION, 2005, 35 : S200 - S200
  • [19] Non-myeloablative HSCT in elderly AML/MDS patients in 1st CR.
    Tibes, R
    de Lima, M
    Estey, E
    Shahjahan, M
    Champlin, R
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 598S - 598S
  • [20] Successful treatment of advanced and refractory AML with sirolimus based non-myeloablative allogeneic stem cell transplantation.
    Claxton, DF
    Ehmann, C
    Rybka, W
    BLOOD, 2004, 104 (11) : 755A - 756A
12345